The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
STAT3 SIGNALING: Anticancer Strategies and Challenges
Open accessAbstract
Multiple lines of evidence place STAT3 at a central node in the development, progression, and maintenance of many human tumors, and STAT3 has been validated as an anti-cancer target in several contexts. STAT3 modulates the transcription of a variety of genes involved in the regulation of critical functions, including cell differentiation, proliferation, apoptosis, angiogenesis, metastasis, and immune responses. For many cancers, elevated levels of activated STAT3 have been associated with a poor prognosis. We review approaches that have been pursued to target STAT3, and we highlight some of the promises and challenges associated with developing an anticancer drug that might therapeutically inhibit the STAT3 signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 11×
“STAT3 is structurally typical of the STAT family: an N-terminal coiled-coiled domain involved in protein–protein interactions; a DNA binding domain; a Src homology-2 (SH-2) domain; and a C-terminal transactivation domain (5, 22).”
BackgroundInfluentialBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04911.x · Cited by 649
SOCS regulation of the JAK/STAT signalling pathway
Croker, B. A., Kiu, H., & Nicholson, S. E. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.010 · Cited by 611
Inhibitors of Cytokine Signal Transduction
Wormald, S., & Hilton, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r300030200 · Cited by 440
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
Silva, C. M. (2004) · Oncogene · doi:10.1038/sj.onc.1208159 · Cited by 403
STAT3 as a central mediator of neoplastic cellular transformation
Frank, D. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.017 · Cited by 364
Cited by
The Role of Resveratrol in Cancer Therapy
Ko, J.-H., Sethi, G., Um, J.-Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., Bishayee, A., & Ahn, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122589 · Cited by 800
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Thymoquinone: Potential cure for inflammatory disorders and cancer
Woo, C. C., Kumar, A. P., Sethi, G., & Tan, K. H. B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.09.029 · Cited by 541
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 507
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
Crescenzo, R., Abate, F., Lasorsa, E., Tabbo’, F., Gaudiano, M., Chiesa, N., Di Giacomo, F., Spaccarotella, E., Barbarossa, L., Ercole, E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.006 · Cited by 443
The role of JAK-STAT signaling within the CNS
Nicolas, C. S., Amici, M., Bortolotto, Z. A., Doherty, A., Csaba, Z., Fafouri, A., Dournaud, P., Gressens, P., Collingridge, G. L., & Peineau, S. (2013) · JAK-STAT · doi:10.4161/jkst.22925 · Cited by 351
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
Platten, M., von Knebel Doeberitz, N., Oezen, I., Wick, W., & Ochs, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00673 · Cited by 340
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.003 · Cited by 340
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Targeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 271
Targeting transcription factor STAT3 for cancer prevention and therapy
Chai, E. Z. P., Shanmugam, M. K., Arfuso, F., Dharmarajan, A., Wang, C., Kumar, A. P., Samy, R. P., Lim, L. H. K., Wang, L., Goh, B. C., et al. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.004 · Cited by 263
Kaempferol, a potential cytostatic and cure for inflammatory disorders
Rajendran, P., Rengarajan, T., Nandakumar, N., Palaniswami, R., Nishigaki, Y., & Nishigaki, I. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.011 · Cited by 259
The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations
Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193
Self-citationChainoglou, E., & Hadjipavlou-Litina, D. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1614560 · Cited by 92
S-Glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation
Butturini, E., Darra, E., Chiavegato, G., Cellini, B., Cozzolino, F., Monti, M., Pucci, P., Dell’Orco, D., & Mariotto, S. (2014) · ACS Chemical Biology · doi:10.1021/cb500407d · Cited by 82
Rammohan, M., Harris, E., Bhansali, R. S., Zhao, E., Li, L. S., & Crispino, J. D. (2022) · Oncogene · doi:10.1038/s41388-022-02245-6 · Cited by 68
Metadata
- Authors
- Johnston, P. A., & Grandis, J. R.
- Venue
- Molecular Interventions
- Publisher
- CLOCKSS Archive
- Published
- 2011-02-01
- Volume
- 11
- Issue
- 1
- Pages
- 18-26
- ISSN
- 1534-0384 (ISSN-L)
- OpenAlex
- W1991013609
- Cited by
- 406
- References
- 38
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.